Scientists hunt for clues to predict blistering disease severity
NCT ID NCT07649486
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at 50 people with bullous pemphigoid, a skin condition that causes blisters. Researchers want to see if certain proteins in skin samples and blood markers like IgE and eosinophil counts are linked to how severe the disease is. The goal is to find better ways to measure disease activity, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict and monitor disease activity in bullous pemphigoid using tissue or blood markers.
- What could go wrong
- This is a small, observational study that does not test a treatment. The findings may not lead to immediate changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2026
- Expected to finish
-
Apr 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients diagnosed with bullous pemphigoid and followed at the University of Health Sciences, Istanbul Training and Research Hospital. Participants will be identified retrospectively from hospital records and pathology archives. Clinical, laboratory, and histopathological data, including BPDAI scores, serum IgE levels, peripheral eosinophil counts, and immunohistochemical expression of periostin and eosinophilic cationic protein, will be evaluated.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥18 years. * Diagnosis of bullous pemphigoid confirmed by compatible clinical, histopathological, and/or direct immunofluorescence findings. * Availability of archived skin biopsy specimens suitable for immunohistochemical evaluation of periostin and eosinophilic cationic protein (ECP). * Availability of clinical and laboratory data, including BPDAI score, serum IgE level, and peripheral eosinophil count. Exclusion Criteria: * Age \<18 years. * Diagnosis other than bullous pemphigoid. * Inadequate or unavailable biopsy specimens for immunohistochemical analysis. * Missing clinical, histopathological, or laboratory data required for study analyses.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bullous pemphigoid (BP) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
S.B.Ü. İstanbul Eğitim ve Araştırma Hastanesi
Istanbul, FATİH, 34096, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.